Cargando…

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension

BACKGROUND: The evidence regarding triple oral combination therapy for patients with pulmonary arterial hypertension (PAH) is scarce. This study was performed to investigate the effectiveness and safety of triple oral combination therapy with macitentan, riociguat, and selexipag. METHODS: Among cons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Momoi, Mizuki, Hiraide, Takahiro, Shinya, Yoshiki, Momota, Hiromi, Fukui, Shogo, Kawakami, Michiyuki, Itabashi, Yuji, Fukuda, Keiichi, Kataoka, Masaharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919213/ https://www.ncbi.nlm.nih.gov/pubmed/33627044 http://dx.doi.org/10.1177/1753466621995048

Ejemplares similares

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension
por: Murata, Mitsushige, et al.
Publicado: (2017)

RNF213-Associated Vascular Disease: A Concept Unifying Various Vasculopathies
por: Hiraide, Takahiro, et al.
Publicado: (2022)

Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　― Protocol of a Multicenter Randomized Control Trial ―
por: Akagi, Satoshi, et al.
Publicado: (2021)

Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report
por: Lattanzio, Mariangela, et al.
Publicado: (2022)

TET2 Variants in Japanese Patients With Pulmonary Arterial Hypertension
por: Hiraide, Takahiro, et al.
Publicado: (2021)

Long-term Follow-up of Qing-Dai–Induced Pulmonary Arterial Hypertension: A Case Series
por: Matsushima, Takahide, et al.
Publicado: (2023)

Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study
por: Kawakami, Takashi, et al.
Publicado: (2020)

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019)

TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension
por: Shinya, Yoshiki, et al.
Publicado: (2021)

Factors related to instrumental activities of daily living in persons with chronic thromboembolic pulmonary hypertension
por: Iwasawa, Tatsuya, et al.
Publicado: (2021)

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects
por: Csonka, Dénes, et al.
Publicado: (2019)

Regional Right Ventricular Abnormalities Implicate Distinct Pathophysiological Conditions in Patients With Chronic Thromboembolic Pulmonary Hypertension
por: Moriyama, Hidenori, et al.
Publicado: (2020)

Exercise prescription using an insertable cardiac monitor in a patient with catecholaminergic polymorphic ventricular tachycardia
por: Momoi, Mizuki, et al.
Publicado: (2021)

Genetic Testing Enables the Diagnosis of Familial Hypercholesterolemia Underdiagnosed by Clinical Criteria: Analysis of Japanese Early-Onset Coronary Artery Disease Patients
por: Miyama, Hiroshi, et al.
Publicado: (2023)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Antiproliferative effect of selexipag active metabolite MRE‐269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension
por: Kuramoto, Kazuya, et al.
Publicado: (2023)

Preoperative Instrumental Activities of Daily Living Predicts Survival After Transcatheter Aortic Valve Implantation
por: Fukui, Shogo, et al.
Publicado: (2020)

Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients
por: Cui, Xiaopei, et al.
Publicado: (2022)

Prognostic value of three-dimensional echocardiographic right ventricular ejection fraction in patients with pulmonary arterial hypertension
por: Murata, Mitsushige, et al.
Publicado: (2016)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2022)

Exercise tolerance and quality of life in hemodynamically partially improved patients with chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty
por: Miura, Kotaro, et al.
Publicado: (2021)

The complement C3-complement factor D-C3a receptor signalling axis regulates cardiac remodelling in right ventricular failure
por: Ito, Shogo, et al.
Publicado: (2022)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Improvement in the electrocardiograms associated with right ventricular hypertrophy after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension
por: Nishiyama, Takahiko, et al.
Publicado: (2018)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

Riociguat: PATENT-1 Study
por: Said, Karim
Publicado: (2014)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Macitentan in the treatment of pulmonary hypertension in Gaucher’s disease
por: Taylan, Gökay, et al.
Publicado: (2020)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
por: Frey, Reiner, et al.
Publicado: (2017)

Combination of rescue balloon pulmonary angioplasty and riociguat therapy for chronic thromboembolic pulmonary hypertension with nonsustained polymorphic ventricular tachycardia: A case report
por: Fukuda, Yoshitake, et al.
Publicado: (2023)

Qualitative and Quantitative Effects of Fatty Acids Involved in Heart Diseases
por: Moriyama, Hidenori, et al.
Publicado: (2022)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Use of selexipag in a teenage patient with pulmonary arterial hypertension
por: Bravo-Valenzuela, Nathalie Jeanne Magioli, et al.
Publicado: (2021)

Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles
por: Luo, Shun-bin, et al.
Publicado: (2021)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tq9r6e1kn2oiupibic9dh6g8da